The antibiotics industry has suffered an alarming collapse that has become even more troubling as secondary bacterial infections threaten patients with COVID-19. Why has production of these vital medicines stagnated, and what can be done to address the problem? Economics correspondent Paul Solman reports on why lifesaving drugs don't necessarily translate to lucrative businesses.
Stream your PBS favorites with the PBS app: [ Ссылка ]
Find more from PBS NewsHour at [ Ссылка ]
Subscribe to our YouTube channel: [ Ссылка ]
Follow us:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Instagram: [ Ссылка ]
Snapchat: @pbsnews
Subscribe:
PBS NewsHour podcasts: [ Ссылка ]
Newsletters: [ Ссылка ]
